(Q46583399)

23 December 2017

title

All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer (English)

1 reference

23 December 2017

1 reference

Hesham Tawfik

1

1 reference

23 December 2017

Yousri Rostom

series ordinal

2

1 reference

23 December 2017

Hesham Elghazaly

series ordinal

3

1 reference

23 December 2017

publication date

24 January 2013

1 reference

23 December 2017

Cancer Chemotherapy and Pharmacology

published in

1 reference

23 December 2017

volume

71

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

913-919

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2082-4

exact match

0 references

cites work

Breast cancer statistics, 2011.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Global trends in breast cancer incidence and mortality 1973-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Capecitabine and vinorelbine in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Patient preferences for oral versus intravenous palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Effective oral chemotherapy for breast cancer: pillars of strength.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

The vital role of education and information in patients receiving capecitabine (Xeloda).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

Implementation of capecitabine (Xeloda) into a cancer centre: UK experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2082-4

10.1007/S00280-013-2082-4

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

23344713

1 reference

23 December 2017